PD-1 Inhibitor

ClinicalJuly 18, 2026

Merck's Pembrolizumab Study Targets Japanese Pediatric and Adult Cancer Patients

Merck is conducting a study to evaluate the safety and efficacy of pembrolizumab in Japanese pediatric participants with solid tumors and lymphomas, as well as in adults with Merkel cell carcinoma.

Companies

Assets

Recent signals(13)

FDA Accepts Supplement Application for KEYTRUDA QLEX by Merck

FDA Submission Update for KEYTRUDA (BLA125514) by Merck

FDA Submission Update for OPDIVO (Nivolumab) by Bristol Myers Squibb

Merck's Pembrolizumab Study Targets Japanese Pediatric and Adult Cancer Patients

FDA Grants Priority Review for KEYTRUDA QLEX Supplement Application

FDA grants priority review for KEYTRUDA supplemental application

FDA Grants Priority Review for KEYTRUDA QLEX Supplement Application

FDA Submission Update for KEYTRUDA (Pembrolizumab) by Merck

FDA Accepts Supplement Application for OPDIVO (Nivolumab) by Bristol Myers Squibb

Phase 2 Study of Tislelizumab in MSI-H or dMMR Solid Tumors by BeiGene

FDA Accepts Supplemental Application for KEYTRUDA QLEX

FDA Approves Supplement for KEYTRUDA (pembrolizumab) by Merck

FDA Grants Priority Review for KEYTRUDA QLEX Supplement Application

Upcoming catalysts

Indications

Get signals before the market moves